Christodoulides Nicolaos, De La Garza Richard, Simmons Glennon W, McRae Michael P, Wong Jorge, Newton Thomas F, Smith Regina, Mahoney James J, Hohenstein Justin, Gomez Sobeyda, Floriano Pierre N, Talavera Humberto, Sloan Daniel J, Moody David E, Andrenyak David M, Kosten Thomas R, Haque Ahmed, McDevitt John T
Department of Bioengineering, Rice University, Houston, TX, USA; Department of Chemistry, Rice University, Houston, TX, USA.
Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA; Department of Pharmacology, Baylor College of Medicine, Houston, TX, USA; Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA.
Drug Alcohol Depend. 2015 Aug 1;153:306-13. doi: 10.1016/j.drugalcdep.2015.04.026. Epub 2015 May 22.
There is currently a gap in on-site drug of abuse monitoring. Current detection methods involve invasive sampling of blood and urine specimens, or collection of oral fluid, followed by qualitative screening tests using immunochromatographic cartridges. While remote laboratories then may provide confirmation and quantitative assessment of a presumptive positive, this instrumentation is expensive and decoupled from the initial sampling making the current drug-screening program inefficient and costly. The authors applied a noninvasive oral fluid sampling approach integrated with the in-development chip-based Programmable bio-nano-chip (p-BNC) platform for the detection of drugs of abuse.
The p-BNC assay methodology was applied for the detection of tetrahydrocannabinol, morphine, amphetamine, methamphetamine, cocaine, methadone and benzodiazepines, initially using spiked buffered samples and, ultimately, using oral fluid specimen collected from consented volunteers.
Rapid (∼10min), sensitive detection (∼ng/mL) and quantitation of 12 drugs of abuse was demonstrated on the p-BNC platform. Furthermore, the system provided visibility to time-course of select drug and metabolite profiles in oral fluids; for the drug cocaine, three regions of slope were observed that, when combined with concentration measurements from this and prior impairment studies, information about cocaine-induced impairment may be revealed.
This chip-based p-BNC detection modality has significant potential to be used in the future by law enforcement officers for roadside drug testing and to serve a variety of other settings, including outpatient and inpatient drug rehabilitation centers, emergency rooms, prisons, schools, and in the workplace.
目前在现场滥用药物监测方面存在空白。当前的检测方法包括对血液和尿液样本进行侵入性采样,或收集口腔液,然后使用免疫层析试纸条进行定性筛查测试。虽然远程实验室随后可能会对推定阳性结果进行确认和定量评估,但这种仪器价格昂贵,且与初始采样脱节,使得当前的药物筛查程序效率低下且成本高昂。作者应用了一种非侵入性口腔液采样方法,并结合了正在开发的基于芯片的可编程生物纳米芯片(p-BNC)平台来检测滥用药物。
将p-BNC检测方法应用于检测四氢大麻酚、吗啡、苯丙胺、甲基苯丙胺、可卡因、美沙酮和苯二氮䓬类药物,最初使用加标的缓冲样本,最终使用从同意参与的志愿者身上收集的口腔液样本。
在p-BNC平台上实现了对12种滥用药物的快速(约10分钟)、灵敏(约纳克/毫升)检测和定量。此外,该系统还能显示口腔液中特定药物和代谢物谱随时间的变化情况;对于可卡因,观察到了三个斜率区域,将这些与本次及之前的损伤研究中的浓度测量结果相结合,可能会揭示有关可卡因所致损伤的信息。
这种基于芯片的p-BNC检测方式在未来有很大潜力供执法人员用于路边药物检测,并服务于各种其他场所,包括门诊和住院药物康复中心、急诊室、监狱、学校以及工作场所。